Board Meeting12 Aug 2026, 12:25 pm
Marksans Pharma Board Approves Q1 FY27 Unaudited Results
AI Summary
Marksans Pharma Ltd announced that its Board of Directors, in a meeting held on August 12, 2026, approved the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). Both consolidated and standalone results were declared. The company's statutory auditors, MSKA & Associates LLP, have provided an unmodified opinion on these results. The detailed financial information is also available on the company's website.
Key Highlights
- Board approved Q1 FY27 unaudited financial results.
- Both consolidated and standalone results were declared.
- Auditors issued an unmodified review report.
- Results are compliant with Ind AS 34 and SEBI regulations.
Price Impact
More from MARKSANS